Target intelligence / Profile preview

Fasciculation and elongation protein zeta-1 (FEZ1)

Target
FEZ1
Molecular classification
Other (scaffold/adaptor protein, hub protein—cytoskeletal and trafficking adaptor)
01

Overview

Fasciculation and elongation protein zeta-1 (FEZ1) is a human protein encoded by the FEZ1 gene, noted for its vital role in neuronal development, particularly in axonal bundling and elongation, as discovered via its ortholog in C. elegans (unc-76)[1][2][3][7]. FEZ1 acts as a scaffold and adaptor in intracellular transport, especially in the kinesin-1–mediated movement of cargos essential for neuronal function and development[2][3]. It is highly expressed in neuronal tissues, particularly in the developing and adult brain, where it participates in neurite outgrowth, protein trafficking, and the regulation of autophagy[2][3]. Structurally, FEZ1 is largely intrinsically disordered, adopts coiled-coil regions, dimerizes via a disulfide bond, and serves as a hub for various protein-protein interactions[2][3][4]. FEZ1 also interacts with key proteins such as Protein kinase Mζ, Kinesin-1, Munc18, Syntaxin 1a, JIP1, NBR1, DISC1, and others, which underlies its role in both neuronal development and autophagy pathways[1][2][3]. Evidence suggests FEZ1 is involved in antiviral cellular defense, notably restricting infection by HIV[5]. To date, FEZ1 is not a recognized pharmacological target and no drugs are known to directly interact with or modulate its function. However, its dysregulation has been associated with neurodevelopmental and neurodegenerative disorders as well as altered susceptibility to viral infections[2][5].

Other names
UNC-76Zygin IZygin-1STT3A-AS1
02

Mechanism of action

Not a direct drug target; no known mechanism of action for drugs

03

Biological functions

Neuronal developmentAxonal growth and fasciculationIntracellular transport (kinesin-mediated axonal transport)Protein-protein interactionsRegulation of autophagyRegulation of gene expressionAntiviral defense
04

Disease associations

Neurodegenerative diseaseNeuropathologiesViral infectionPotentially other neurological disorders
05

Safety considerations

Not applicable—no known direct therapeutic targeting or clinical safety concerns established

Beyond the preview

Go deeper on Fasciculation and elongation protein zeta-1 (FEZ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fasciculation and elongation protein zeta-1 (FEZ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call